Total CD4+T cell counts in PB (cells/ µL) 10 years after commencement of therapy assuming no ×4 virus in these simulations when therapy is delivered to CD4+T cells – medians (5%, 95%) from sensitivity analyses.

Median final total CD4+T cell counts in PB (cells/ µL) 10 years after commencement of therapy when therapy is delivered to CD4+T cells, assuming no ×4 virus in these simulations (i.e. for all times ). Also shown are the 5th and 95th percentile values of final CD4+T cell counts from the parameter sensitivity analysis. Simulation outcomes are shown for the standard scenario (STD) and under Assumption +A1 of reduced bystander apoptosis in G+ CD4+T cells. Outcomes are also shown for the case that therapy is delivered as one-off treatment, every 2 years or every 1 year. Cases that 10%, 20%, 30%, 40% and 50% of cells receive the gene construct are also simulated. First time of therapy administration was either 1 year, 4 years or 7 years post-PHI.